New lung cancer cocktail aims to outperform current standard therapy
NCT ID NCT07662811
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This clinical trial compares a new three-drug combination (SYHX2011, carboplatin, and enlonstobart) against the standard three-drug regimen (nab-paclitaxel, carboplatin, and tislelizumab) as a first treatment for people with advanced squamous non-small cell lung cancer. The study includes about 396 adults whose tumors have a specific marker (PD-L1 ≥1%) and who have not had prior systemic therapy. The goal is to see if the new combination shrinks tumors more effectively and delays cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SYHX2011 (a form of paclitaxel), carboplatin, enlonstobart
What this could lead to
If successful, this combination could offer a more effective first-line treatment option for people with advanced squamous non-small cell lung cancer.
What could go wrong
This is a phase II/III trial, so results are not yet confirmed. The new combination may not prove better than the standard therapy and could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.